UH Clinical Trial Could Lead to Bladder Cancer Drug

/, Features, Home Page Slideshow/UH Clinical Trial Could Lead to Bladder Cancer Drug

UH Clinical Trial Could Lead to Bladder Cancer Drug

Dr. Charles Rosser, director of the UH Cancer Center’s Clinical Trials Office

Dr. Charles Rosser, director of the UH Cancer Center’s Clinical Trials Office

A bladder cancer drug tested in a University of Hawaiʻi Cancer Center clinical trial gets closer to Food and Drug Administration approval. The new drug, an interleukin 15 superagonist complex (ALT-803), combined with Bacillus Calmette-Guerin (BCG) is expected to be more effective for patients with non-muscle invasive bladder cancer, the most common type of bladder cancer, as reported by UH.

“The last time the FDA approved a drug for bladder cancer was almost two decades ago. Bladder cancer treatment hasn’t advanced very much, BCG has been the main drug used to treat the disease since the ’80s,” said Dr. Charles Rosser, director of the UH Cancer Center’s Clinical Trials Office. “The science field has changed so much since then. We may finally be able to move the field forward and get better drugs to patients.”

Phase II of the study was recently Institutional Review Board and FDA approved. The first patient for Phase II was enrolled on Oct. 15. The Phase II study will have about 124 participants; most of them will be from Hawaiʻi. The goal of this phase is to show improved outcomes for cancer patients.

“At least five other academic centers on the Mainland are opening this clinical trial because of encouraging preclinical studies in addition to the Phase I clinical trial results. It is exciting because it started here in Hawaiʻi and other patients across the country, even across the world, may see positive results as well,” Rosser said.

Phase I of the study with about nine participants was completed last summer. At least 20 percent of the participants were expected to have a recurrence of bladder cancer by now, but so far no patients have. Overall, bladder cancer has a high recurrence rate of more than 50 percent.

“I knew this drug had positive results in the lab, so I didn’t hesitate to be a part of this clinical trial. I thought well I have bladder cancer, my wife had breast cancer about 7 years ago, so she said we have to do what we can,” said Clark Morgan, a Kailua resident and Phase I clinical trial participant. “I thought it was convenient that I could stay in Hawaiʻi to get this treatment, I don’t know if I would have gone if it was on the Mainland.”

Nationally, there are 74,000 new cases of bladder cancer and an estimated 16,000 deaths every year according to the National Cancer Institute. It is ranked in the top five cancers for men in the U.S. The disease occurs more in men than women.

Phase I showed that the trial was well-tolerated, and also demonstrated the recommended dose to be tested in Phase II. Researchers aim to get the ALT-803 drug created by Altor BioScience Corporation FDA approved.

 

By | 2016-11-10T05:40:51+00:00 December 11th, 2015|0 Comments

About the Author:

Léo Azambuja, editor of For Kaua‘i, has won multiple journalism awards in the state of Hawai‘i, including investigative and enterprise reporting, spot news and feature writing, photojournalism and online reporting.

Leave a Reply